Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 23:48 UTC |
Crouse Steven C.President - Diag & Spatial Bi
|
GrantPerformance Restricted Stock Units · Derivative | 2,387 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000036 · form4.xml · derivative · entry 15 Crouse Steven C. · CIK 0002065241 · President - Diag & Spatial Bi 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,387 Underlying: Common Stock · 2,387 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F14 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F14 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:57 UTC |
Herr Amy E.Director
|
SaleCommon Stock | 1,976 | $59.11 | $116,791.48 |
DisclosureSEC source: 0000914190-26-000030 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 200 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.091 to $59.1390, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:30 UTC |
Herr Amy E.Director
|
Exercise / conversionRestricted Stock Units · Derivative | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000011 · form4.xml · derivative · entry 15 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 77 Underlying: Common Stock · 38 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. F10 · derivative.expiration_date: 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:30 UTC |
Herr Amy E.Director
|
Tax withholdingCommon Stock | 16 | $64.63 | $1,034.08 |
DisclosureSEC source: 0000914190-26-000011 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,176 Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:30 UTC |
Herr Amy E.Director
|
Exercise / conversionCommon Stock | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000011 · form4.xml · nonDerivative · entry 2 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 22:04 UTC |
McManus MatthewPresident - Diag & Spatial Bio
|
Exercise / conversionRestricted Stock Units · Derivative | 4,621 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000009 · form4.xml · derivative · entry 5 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,620 Underlying: Common Stock · 4,621 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: 4,621 restricted stock units vest on 2/1/2026 and 4,620 restricted stock units vest on 2/1/2027. F3 · derivative.expiration_date: 4,621 restricted stock units vest on 2/1/2026 and 4,620 restricted stock units vest on 2/1/2027. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 22:04 UTC |
McManus MatthewPresident - Diag & Spatial Bio
|
Tax withholdingCommon Stock | 1,665 | $64.09 | $106,709.85 |
DisclosureSEC source: 0000914190-26-000009 · form4.xml · nonDerivative · entry 2 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,691 Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 22:04 UTC |
McManus MatthewPresident - Diag & Spatial Bio
|
Exercise / conversionCommon Stock | 4,621 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000009 · form4.xml · nonDerivative · entry 1 McManus Matthew · CIK 0001908268 · President - Diag & Spatial Bio 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC |
Kelderman KimDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 2,303 | $62.57 | $144,098.71 |
DisclosureSEC source: 0000914190-25-000031 · form4.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,665 Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionRestricted Stock Units · Derivative | 9,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000029 · form4.xml · derivative · entry 8 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,911 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 9,911 restricted stock units vest on 11/1/2025. F6 · derivative.expiration_date: 9,911 restricted stock units vest on 11/1/2025. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Tax withholdingCommon Stock | 4,520 | $62.57 | $282,816.40 |
DisclosureSEC source: 0000914190-25-000029 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,503 Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC |
Geist WilliamPRESIDENT, PROTEIN SCIENCES
|
Exercise / conversionCommon Stock | 9,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000029 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC |
Hippel JamesCFO
|
Exercise / conversionRestricted Stock Units · Derivative | 11,545 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,089 Underlying: Common Stock · 11,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F10 · derivative.exercise_date: 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. F10 · derivative.expiration_date: 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC |
Hippel JamesCFO
|
Exercise / conversionRestricted Stock Units · Derivative | 13,159 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · derivative · entry 11 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F6 · derivative.exercise_date: 13,159 restricted stock units vest on 11/1/2025. F6 · derivative.expiration_date: 13,159 restricted stock units vest on 11/1/2025. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC |
Hippel JamesCFO
|
Tax withholdingCommon Stock | 11,865 | $62.57 | $742,393.05 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,722 Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 11,545 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 13,159 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:37 UTC |
KEEGAN JOSEPH DDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000024 · form4.xml · derivative · entry 10 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:37 UTC |
KEEGAN JOSEPH DDirector
|
GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000024 · form4.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,411 Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:38 UTC |
Bushman Julie LDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000025 · form4.xml · derivative · entry 8 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:38 UTC |
Bushman Julie LDirector
|
GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000025 · form4.xml · nonDerivative · entry 1 Bushman Julie L · CIK 0001518599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,775 Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:25 UTC |
HIGGINS JOHN LDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000021 · form4.xml · derivative · entry 11 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:25 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000021 · form4.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,876 Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:23 UTC |
Klimovsky Judith V.Director
|
GrantStock Option (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000018 · form4.xml · derivative · entry 4 Klimovsky Judith V. · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:23 UTC |
Klimovsky Judith V.Director
|
GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000018 · form4.xml · nonDerivative · entry 1 Klimovsky Judith V. · CIK 0001762247 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,782 Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:25 UTC |
Seth AlpnaDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000020 · form4.xml · derivative · entry 8 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:25 UTC |
Seth AlpnaDirector
|
GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000020 · form4.xml · nonDerivative · entry 1 Seth Alpna · CIK 0001721020 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,411 Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:24 UTC |
Herr Amy E.Director
|
GrantStock Option (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000019 · form4.xml · derivative · entry 4 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:24 UTC |
Herr Amy E.Director
|
GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000019 · form4.xml · nonDerivative · entry 1 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,680 Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:23 UTC |
Vessey RupertDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000017 · form4.xml · derivative · entry 9 Vessey Rupert · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:23 UTC |
Vessey RupertDirector
|
GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000017 · form4.xml · nonDerivative · entry 1 Vessey Rupert · CIK 0001677618 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,987 Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:22 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Options (Right to Buy) · Derivative | 3,777 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0000914190-25-000016 · form4.xml · derivative · entry 11 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,777 Underlying: Common Stock · 3,777 shares Expires 2035-10-30 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. Read SEC document |
| October 30, 2025 Filed Nov 3, 2025 22:22 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 1,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000016 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,503 Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:09 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 17,040 | $0.00 Strike: $21.84 | $0.00 |
DisclosureSEC source: 0001062993-25-014992 · form4.xml · derivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,040 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:09 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 17,040 | $56.21 | $957,818.40 |
DisclosureSEC source: 0001062993-25-014992 · form4.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,863 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.97 to $56.34 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:09 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 17,040 | $21.84 | $372,153.60 |
DisclosureSEC source: 0001062993-25-014992 · form4.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:10 UTC |
Nusse RoelandDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 17,040 | $0.00 Strike: $21.84 | $0.00 |
DisclosureSEC source: 0001062993-25-014993 · form4.xml · derivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,040 shares Expires 2025-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:10 UTC |
Nusse RoelandDirector
|
SaleCommon Stock | 17,040 | $56.36 | $960,388.03 |
DisclosureSEC source: 0001062993-25-014993 · form4.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,559 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.21 to $56.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:10 UTC |
Nusse RoelandDirector
|
Exercise / conversionCommon Stock | 17,040 | $21.84 | $372,153.60 |
DisclosureSEC source: 0001062993-25-014993 · form4.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC |
Hippel JamesCFO
|
GrantStock Options (Right to Buy) · Derivative | 37,632 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · derivative · entry 17 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,632 Underlying: Common Stock · 37,632 shares Expires 2035-08-15 F13 · derivative.exercise_date: Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC |
Hippel JamesCFO
|
GrantRestricted Stock Units · Derivative | 14,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · derivative · entry 16 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,710 Underlying: Common Stock · 14,710 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F12 · derivative.exercise_date: 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. F12 · derivative.expiration_date: 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC |
Hippel JamesCFO
|
GrantPerformance Restricted Stock Units · Derivative | 29,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,420 Underlying: Common Stock · 29,420 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F11 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC |
Hippel JamesCFO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · derivative · entry 12 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,021 Underlying: Common Stock · 4,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F8 · derivative.exercise_date: 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027. F8 · derivative.expiration_date: 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC |
Hippel JamesCFO
|
Tax withholdingCommon Stock | 1,926 | $53.60 | $103,233.60 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,883 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC |
Hippel JamesCFO
|
Exercise / conversionCommon Stock | 4,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC |
Herr Amy E.Director
|
GrantStock Option (Right to Buy) · Derivative | 2,735 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · derivative · entry 16 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,735 Underlying: Common Stock · 2,735 shares Expires 2035-08-15 F13 · derivative.exercise_date: Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC |
Herr Amy E.Director
|
GrantRestricted Stock Units · Derivative | 932 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · derivative · entry 15 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 932 Underlying: Common Stock · 932 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028. F12 · derivative.expiration_date: 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC |
Herr Amy E.Director
|
Exercise / conversionRestricted Stock Units · Derivative | 160 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · derivative · entry 13 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 320 Underlying: Common Stock · 160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. F10 · derivative.expiration_date: 160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC |
Herr Amy E.Director
|
Exercise / conversionRestricted Stock Units · Derivative | 119 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · derivative · entry 12 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 118 Underlying: Common Stock · 119 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026. F9 · derivative.expiration_date: 119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:29 UTC |
Herr Amy E.Director
|
Tax withholdingCommon Stock | 101 | $53.60 | $5,413.60 |
DisclosureSEC source: 0001062993-25-014701 · form4.xml · nonDerivative · entry 3 Herr Amy E. · CIK 0002055523 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By significant other Disclosed balance after: 2,154 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.